Cellectar Biosciences Inc. Common Stock (CLRB)
Stock · NASDAQ · Health Care
$1.15as of 10/16/2026
Price chart
Active signals
CLRB Signal Track Record
How signals performed across all stocks →What CLRB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 24 | -13.6% | 25% | October 6, 2026 |
| Bollinger Band Breakout | 20 | -10.0% | 30% | May 5, 2026 |
| Bollinger Band Breakdown | 13 | -7.8% | 15% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -16.6% | 0% | May 29, 2024 |
| Any 20-session window (baseline) | -3.4% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 11
- Website
- www.cellectar.com/
Fundamentals
- 1-day range
- $1.12$1.28
- Market cap
- $20.14M
- P/E (trailing)
- —
- P/E (forward)
- -0.60
- EPS (trailing)
- $-4.59
- Dividend yield
- —
- Beta
- 0.58
- Avg. volume
- 71.7K
- Dividend pay date
- July 17, 2018
Forecasts
4 analyst ratings
Cellectar Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CLRBCellectar Biosciences Inc. Common Stock$1.14▼ 4.20%Market cap $20.14MP/E —$1.15$5.07
- NXTCNextCure Inc. Common Stock$6.24▼ 9.30%Market cap $20.19MP/E —$1.55$15.74
- DAREDare Bioscience Inc. Common Stock$0.725▼ 2.03%Market cap $19.92MP/E —$0.69$3.78
- GRDXGridAI Technologies Corp. Common Stock$4.22▼ 5.38%Market cap $19.91MP/E —$1.87$6.93
- CELUCelularity Inc. Class A Common Stock$1.25▼ 6.02%Market cap $19.77MP/E —$0.5601$2.55
- RKTORocket One Inc. Common Stock$0.507▼ 5.59%Market cap $19.75MP/E —$0.51$2.45
- QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$2.47▼ 8.86%Market cap $20.67MP/E —$2.85$23.1
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CLRB Cellectar Biosciences Inc. Common Stock | $20.14M | — | $1.14 | ▼ 4.20% | $1.15$5.07 |
| NXTC NextCure Inc. Common Stock | $20.19M | — | $6.24 | ▼ 9.30% | $1.55$15.74 |
| DARE Dare Bioscience Inc. Common Stock | $19.92M | — | $0.725 | ▼ 2.03% | $0.69$3.78 |
| GRDX GridAI Technologies Corp. Common Stock | $19.91M | — | $4.22 | ▼ 5.38% | $1.87$6.93 |
| CELU Celularity Inc. Class A Common Stock | $19.77M | — | $1.25 | ▼ 6.02% | $0.5601$2.55 |
| RKTO Rocket One Inc. Common Stock | $19.75M | — | $0.507 | ▼ 5.59% | $0.51$2.45 |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $20.67M | — | $2.47 | ▼ 8.86% | $2.85$23.1 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Loren Stefan · July 8, 2026 · Grant15.0K
- Chanan-Khan Asher · July 7, 2026 · Grant25.0K
- Gu Andrew · July 7, 2026 · Grant25.0K
- Jarrod Longcor · July 7, 2026 · Grant118.0K
- Douglas J. Swirsky · July 7, 2026 · Grant37.5K
- James Caruso V · July 7, 2026 · Grant250.0K
- John Neis · July 7, 2026 · Grant25.0K
- DRISCOLL FREDERICK W · July 7, 2026 · Grant25.0K
- Chad J. Kolean · July 7, 2026 · Grant92.0K
- Jarrod Longcor · May 7, 2026 · Buy26.0K @ $0.01
- Jarrod Longcor · May 7, 2026 · Buy8.7K @ $2.88
- James Caruso V · May 7, 2026 · Buy26.0K @ $0.01
- James Caruso V · May 7, 2026 · Buy8.7K @ $2.88
Institutional Ownership
March 31, 2026
- Total shares held
- 293.6K
- Total value held
- $769.4K
- Institutional holders
- 17
- Unknown100.0K
- Unknown81.9K
- Unknown52.8K
- Unknown18.9K
- Unknown13.9K
- Unknown10.4K
- Unknown9.6K
- Unknown4.7K
- Unknown793
- Unknown510
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cellectar to Present Iopofosine Data at Waldenström Workshop
Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.
Cellectar to Present Iopofosine Data at Waldenström Workshop. Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.